Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;14(11):1893-1894.
doi: 10.4103/1673-5374.259609.

Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders

Kazuki Terada  1 , Keisuke Migita  2 , Yukari Matsushima  3 , Chiaki Kamei  3
Affiliations

Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders

Kazuki Terada et al. Neural Regen Res. 2019 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Enhancement of nerve growth factor (NGF)/TrkA signaling by sigma-2 receptors (Sig-2R) in neurite outgrowth. Sig-2R associates with TrkA signaling to activate phosphorylation of TrkA receptor downstream signaling molecules (e.g., Ras/ERK1/2 and PI3K/Akt) in the cytoplasm. In this model, Sig-2R-mediated potentiation of NGF-induced neurite outgrowth occurs by enhancing the phosphorylation of Akt and/or ERK1/2. ER: Endoplasmic reticulum.
See this image and copyright information in PMC

References

    1. Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC. Identification of the gene that codes for the sigma2 receptor. Proc Natl Acad Sci U S A. 2017;114:7160–7165. - PMC - PubMed
    1. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin. 2005;21:1317–1327. - PubMed
    1. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918–934. - PMC - PubMed
    1. Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease. Alzheimers Dement (N Y) 2019;5:20–26. - PMC - PubMed
    1. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A. 1996;93:8072–8077. - PMC - PubMed